CASP3 and obesity due to melanocortin 4 receptor deficiency: This leads to multiple future therapeutically relevant opportunities: Obesity Treatment: Modulating SPTBN1 expression or function could provide a novel therapeutic strategy to combat obesity by inhibiting the Caspase-3–SPTBN1 axis and its downstream effects.